{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Toxicities will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"},{"description":"Participants with newly diagnosed Monoclonal Ig DepositionDisease (MIDD)","id":"OG001","title":"Monoclonal Ig DepositionDisease (MIDD)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Participants Evaluated for Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}